BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28602036)

  • 1. Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.
    Hofmann JN; Mailankody S; Korde N; Wang Y; Tageja N; Costello R; Zingone A; Hultcrantz M; Pollak MN; Purdue MP; Landgren O
    Obesity (Silver Spring); 2017 Aug; 25(8):1317-1320. PubMed ID: 28602036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Immunotyping Distribution of Serum Monoclonal Paraprotein and Environmental Impact on Multiple Myeloma (MM) and Monoclonal Gammopathy of Uncertain Significance (MGUS) in Taiwan: A Medical Center-Based Experience.
    Chang CC; Su MJ; Lee SJ; Tsai YH; Kuo LY; Lin IH; Huang HL; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2016; 17(1):395-9. PubMed ID: 26838245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
    Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima.
    Fujimura K; Sugiyama A; Akita T; Ohisa M; Nagashima S; Katayama K; Maeda R; Tanaka J
    Int J Hematol; 2021 Apr; 113(4):576-585. PubMed ID: 33389658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Br J Cancer; 2017 Sep; 117(6):835-839. PubMed ID: 28728165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.
    Georgakopoulou R; Andrikopoulou A; Sergentanis TN; Fiste O; Zagouri F; Gavriatopoulou M; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):361-367. PubMed ID: 33582053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.
    Gkotzamanidou M; Christoulas D; Souliotis VL; Papatheodorou A; Dimopoulos MA; Terpos E
    Med Sci Monit; 2013 Dec; 19():1188-94. PubMed ID: 24355943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.
    Bosseboeuf A; Seillier C; Mennesson N; Allain-Maillet S; Fourny M; Tallet A; Piver E; Lehours P; Mégraud F; Berthelot L; Harb J; Bigot-Corbel E; Hermouet S
    Front Immunol; 2020; 11():854. PubMed ID: 32536913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Unexpected symptoms of monoclonal gammopathy].
    Smit PM; Abrahams AC; Schutgens RGE; Notermans NC; Minnema MC
    Ned Tijdschr Geneeskd; 2017; 161():D1741. PubMed ID: 29027517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.
    Landgren O; Shim YK; Michalek J; Costello R; Burton D; Ketchum N; Calvo KR; Caporaso N; Raveche E; Middleton D; Marti G; Vogt RF
    JAMA Oncol; 2015 Nov; 1(8):1061-8. PubMed ID: 26335650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.